Form 4: Incyte Corp Executive Pablo J Cagnoni Reports Stock and Option Transactions

Pablo J Cagnoni, President of R&D at Incyte Corp, reports acquisition of stock and options, as well as shares withheld for tax obligations.

Summary

• On July 15, 2024, Pablo J Cagnoni, President of R&D at Incyte Corp, reported transactions involving Incyte's common stock and employee stock options.
• Cagnoni acquired 19,851 shares of common stock through a restricted stock unit (RSU) award that vests 25% annually over four years.
• 749 shares were withheld by Incyte to satisfy tax obligations related to the settlement of previously reported RSUs at a price of $64.25 per share.
• Cagnoni also acquired 44,411 employee stock options with an exercise price of $64.25, expiring on 07/14/2034.
• These options become exercisable in 37 installments, with 25% vesting after one year and the remainder vesting monthly over three years.
• Following these transactions, Cagnoni beneficially owns 221,170 shares of common stock and 44,411 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The transactions reflect standard equity compensation practices, indicating confidence from the executive in the company's future.

Positives

• The acquisition of 19,851 shares through RSUs indicates confidence in the company's future performance.
• The grant of 44,411 employee stock options incentivizes Cagnoni to contribute to the company's long-term success.

Negatives

• The withholding of 749 shares to cover tax obligations reduces Cagnoni's overall shareholding, although this is a standard procedure.

Risks

• The value of the acquired stock and options is subject to market fluctuations and the company's performance.
• The vesting of the RSUs is contingent upon Cagnoni's continued service with Incyte.

Future Outlook

The reported transactions suggest a continued alignment of executive interests with shareholder value through equity-based compensation.

Industry Context

Form 4 filings are routine disclosures that provide transparency into the trading activities of company insiders, offering insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and stock options, is a common practice among publicly traded companies, particularly in the biotechnology and pharmaceutical industries, to incentivize executives and align their interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation structures for their executives.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and ownership.
• The equity-based compensation structure aligns management's interests with those of shareholders.

Key Dates